Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase ("D5D"). The compounds have a general Formula (I): wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I)..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 09. Juni Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

ALLEN JENNIFER R [VerfasserIn]
AMEGADZIE ALBERT [VerfasserIn]
BOURBEAU MATTHEW P [VerfasserIn]
CHEN NING [VerfasserIn]
GOODMAN CLIFFORD [VerfasserIn]
LATTANZI GIULIA [VerfasserIn]
LINGARD IAIN [VerfasserIn]
LIU QINGYIAN [VerfasserIn]
LOW JONATHAN D [VerfasserIn]
MA VU VAN [VerfasserIn]
MINATTI ANA E [VerfasserIn]
POZZAN ALFONSO [VerfasserIn]
REEVES COREY [VerfasserIn]
SIEGMUND AARON C [VerfasserIn]
TASSINI SABRINA [VerfasserIn]
TONELLI FEDERICA [VerfasserIn]
WALTON MARY [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-06-09, Last update posted on www.tib.eu: 2023-05-21, Last updated: 2023-06-06

Patentnummer:

AU2020391161

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA015311457